Tenofovir Alafenamide Remains the Most Effective Treatment for Chronic HBV
VIENNA -- Tenofovir alafenamide (TAF; Biktarvy) continued to be highly effective for chronic hepatitis B virus…
Browsing Tag
HBV
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and…
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep…
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes…
SAN MATEO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and liver diseases, announces the successful…
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
<!-- Name:DistributionId Value:8810464 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Tenofovir, Vaccine Combo Eliminates Mom-to-Child HBV Transmission
Earlier maternal tenofovir disoproxil fumarate (TDF) combined with infant vaccination completely eliminated vertical…
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting…
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data…
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data…
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical…
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™…
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus…
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining…
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus…
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New…
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm…